A reverse hemolytic plaque-forming cell b4 or b5 Ig reacted with anti-b4 or anti-b5 antibody-coated erythrocytes.
Antibody-secreting cells can be identified by the plaqueforming cell (PFC) assay (1) . The PFC assays are based on the hemolytic reaction of the secreted antibody with antigenic determinants either native to (1) (2) (3) or artificially coupled to (4-6) erythrocytes. Thus, only cells secreting immunoglobulin (Ig) with known antibody specificity can be enumerated.
Thus far, detection of cells secreting Ig with unknown antibody activity by a PFC assay has not been achieved. Here we report the detection of such cells in rabbits by a PFC assay based on the allotypic antigenic properties of the secreted Ig, i.e., the b4 and b5 specificities present on the kappa chain of Ig and controlled by allelic genes. In the assay, the secreted Abbreviations: Ig, immunoglobulin; PFC, plaque-forming cells; RFC, rosette-forming cells; SRBC, sheep red blood cells. * Presented in part at the 57th Annual Meeting of the Federation of American Societies for Experimental Biology, Atlantic City, N.J., April 15-20, 1973. t On leave from CNEN, Rome, Italy. I Passed away suddenly at the age of 28 on August 8, 1973. b4 or b5 Ig reacted with anti-b4 or anti-b5 antibody-coated erythrocytes.
MATERIALS AND METHODS
Antisera and Purified Antibodies. Antisera to rabbit Ig allotypes b4 or b5 were produced and characterized as previously described (7) . Anti-SRBC (sheep red blood cells) antisera were elicited in b4b4 and b5bM homozygous rabbits by weekly intravenous injections of a 1-ml suspension of 2.5%
washed SRBC in saline for 2 months. Anti-b4 or anti-b5 anti-allotype antibodies were isolated by elution from immunosorbents prepared by coupling the b4 or b5 IgG to Sepharose 4B (8) . The adsorbed antibodies were eluted with 0.2 M glycine sulfate buffer, pH 2.2, or with 1 M acetic acid and the acidic eluates were immediately neutralized with 3 M Tris base and dialyzed against saline. Anti-SRBC antibodies were purified by elution from SRBC by a method similar to that of Bratcher et al. (9) . Essentially the SRBC were first incubated with the antisera at 20°for 2 hr and at 40 overnight. The SRBC were washed and then lysed with digitonin (Nutritional Biochemical Corp., Cleveland, Ohio) (1 mg/ml of a 10% SRBC suspension) at 40 overnight. The antibodies were eluted from the washed stroma with 1 M propionic acid and the eluates were immediately neutralized with 3 M Tris base and dialyzed against saline.
Hybrid Antibodies (Anti-SRBC/Anti-allotype). Hybrid antibody molecules were formed by recombination of half molecules of purified anti-allotype and anti-SRBC antibody preparations according to the method of Nisonoff and his coworkers (10, 11) . The antibodies to be hybridized were matched so as to have identical allotypic specificities on their light chain to prevent an antigen-antibody reaction between the anti-SRBC antibody and the anti-allotype antibody. Equal amounts of anti-allotype and anti-SRBC antibodies at a concentration of 5-10 mg/ml were mixed and dialyzed against 0.1 M Tris-HCl buffer, pH 8. was dialyzed against 0.01 M phosphate-buffered saline, pH 7.2. This method leads to a random recombination of half molecules so as to yield three populations of molecules in a 1:2:1 ratio as follows: bivalent anti-SRBC, hybrid anti-SRBC/anti-allotype, and bivalent anti-allotype antibodies. The reformed bivalent anti-SRBC antibodies if left, would agglutinate and lyse the SRBC. Therefore, the hybrid preparations were passed through a b4 or b5 immunosorbent. The effluents containing the unwanted bivalent anti-SRBC antibody were discarded. The eluates obtained by acidic elution contained the desired hybrid antibodies as well as the bivalent anti-allotype anti-bodies. After neutralization and dialysis against saline, the eluates were used for coating the SRBC without further purification since the reformed bivalent antiallotype antibodies do not react with SRBC. Approximately 30-40% of the antibodies initially mixed were recovered as a mixture of hybrid and bivalent anti-allotype antibodies.
Coating of SRBC with Anti-Allotype Antibody. The hybrid antibody preparations were used to coat SRBC through the binding site directed against SRBC. SRBC (1010 cells) were incubated with either the anti-b4 or anti-b5 hybrid antibody preparation (usually 0.2-0.5 mg) in a final volume of 2 ml of saline at 200 for 30 min and then washed with saline. The anti-b4 and anti-b5 coated cells were tested for hemagglutination and hemolysis with the respective b4 and b5 antigens (12) .
Cell Suspension. Rabbit organs (spleen, popliteal lymph node, thymus, and bone marrow from the tibia) were removed and teased with needles in Hanks' solution at 4°. After removal of tissue fragments by settling, the cells were washed two times at 40 and resuspended in Hanks' solution at suitable concentrations. By the trypan blue exclusion method, the cell viability was greater than 85%.
Plaque-Forming Cell Assay. The method described by Jerne et al. (1) was followed with minor modifications. In this order, 0.1 ml of a 12% suspension of anti-allotype-coated SRBC and 0.1 ml of the cell suspensions at various cell concentrations were pipetted in a 100 X 75-mm tube containing 1 ml of 0.8% agarose (Sea Plaque, Marine Colloids, Inc., Rockland, Maine) in Hanks' solution pH 7.4 at 37°. The contents of the tube were mixed and plated on a 60-mm Falcon plastic petri dish, precoated with 3 ml of 1% agarose (Seakem, Marine Colloids, Inc.) in Hanks' solution. After gelification of the top layer the dishes were incubated at 370 for 2 hr in a humid, 5% CO2 atmosphere and then flooded with 2 ml of saline or an optimal dilution (usually 1:200) of anti-b4 or anti-b5 antiserum ("enhancing antiserum") in saline. The dishes were then kept at 40 overnight. The next morning, after decantation, 1 ml of complement solution (reconstituted guinea-pig serum) (Gibco, Grand Island, N.Y.) diluted 1:10 in Hanks' solution was added and the dishes were incubated at 37°for 1-2 hr.
In every experiment, serial concentrations of cells were tested in duplicate or triplicate, and in some experiments the plaques were counted by two or three individuals. (Fig. 1) . The macroscopic and microscopic morphology of these hemolytic plaques was similar to that described by Jerne (1) (Table 1) . As expected, the b4b5 cells formed plaques with the anti-b4-and with the anti-b5-coated SRBC; the combined number of b4 and b5 plaques was approxi- antiserum was incorporated into the gel, whereas normal serum had no inhibitory effect (Fig. 3) . This inhibition was dose-dependent, i.e., the number of plaques decreased with increasing amounts of antiserum. In a similar experiment, (Table 2) .
Also, there was no correlation between the percentages of PFC and RFC, i.e., the number of PFC was not predictable from the number of RFC and vice versa ( Table 2) . DISCUSSION A unique plaque-forming cell (PFC) assay for the enumeration of immunoglobulin-(Ig)secreting cells in nonimmunized rabbits was developed by using sheep erythrocytes (SRBC) coated with anti-Ig antibody. In principle, the Ig secreted by a single cell reacted with the anti-Ig antibody-coated SRBC and upon addition of complement formed a hemolytic plaque. More specifically, SRBC were coated with hybrid antibody having one specificity directed against SRBC and the other specificity against an Ig antigen (i.e., the b4 or b5 kappa chain allotype). These antibody-coated SRBC become reactive with the corresponding antigen, e.g., the anti-b4-coated SRBC were agglutinated by b4 IgG but not by b5 IgG and vice versa. Spleen cells from nonimmunized rabbits when plaqueassayed with the corresponding anti-allotype anti-body-coated SRBC formed hemolytic plaques. These plaques were cellcentered, suggesting that they were formed by cells secreting Ig allotype molecules. Lymphoid cells of b4 homozygous rabbits formed hemolytic plaques with anti-b4-coated SRBC but not with anti-b5-coated SRBC, whereas b5 lymphoid cells formed hemolytic plaques with anti-b5-but not with anti-b4-coated SRBC. Moreover, b4b5 heterozygous lymnphoid cells formed hemolytic plaques with anti-b4-and with anti-b5-coated SRBC. Since the correct matching of the allotype secreted by the cells with the anti-allotype-coated SRBC was an absolute requirement for plaque formation, hemolytic plaques formed by rabbit spleen cells with anti-allotype antibody-coated SRBC were allotype-specific.
The allotypic specificity of these hemolytic plaques was confirmed by the finding that anti-b4 antibody present in the gel during the secretion period inhibited the formation of b4 allotype plaques by competing for the secreted b4 allotype with the anti-b4 antibody bound to SRBC. Similar inhibition of b5 plaques was found by incorporation of anti-b5 antibody in the gel. Moreover, anti-b4 antibody added after the secretion, i.e., when the secreted b4 Ig had already been bound by anti-b4-coated SRBC, enhanced the formation of plaques, presumably by enhancing the fixation of complement. The method first described by Jerne et al. (1) 
